Search with one or more keywords


This page gives you access to all the studies carried out by French researchers, identified on Covid-19.

To view other resources related to Covid-19, click here.


xml
XML

Export to XML

Please choose the format :

pdf
PDF

Export to PDF

Which version do you want to export ?

csv
CSV (Excel)

Export to CSV

What sections do you want to export ?

Métadonnées
Identification
General Aspects
Scientific investigator(s) (Contact)
Collaborations
Funding
Governance of the database
Additional contact
Type of database
Database objective
Population type
Dates
Size of the database
Data
Procedures
Promotion
Access
Select all | Invert selection | No selection

ARCHIVES : 309 forms

Sorting of results :

ADHOC - Observational study on the various arrangements for caring for patients with type-2 diabetes treated by associating oral diabetes medication and insulin

Head : VIGNAL Franck, Sanofi Aventis

Version 1
Overview

91

Last update : 01/01/2018

ARCHIVE

ADHOC - Observational study on the various arrangements for caring for patients with type-2 diabetes treated by associating oral diabetes medication and insulin

Head : VIGNAL Franck, Sanofi Aventis

Main objective

Describe the various arrangements for caring for patients with type-2 diabetes treated by associating oral diabetes medication and insulin as well as their repercussion on HbA1c

Inclusion criteria

man or woman, over the age of 18 years, having type-2 diabetes treated by the association
of oral diabetes medication and insulin for at least 6 months, accepting to participate in the study

PREFACE - Study on the prevalence of facial lipoatrophy in patients infected by HIV virus receiving antiretroviral drugs - FRAN08-005

Head : Cohen-Codar Isabelle

Version 3
Overview

92

Last update : 07/01/2019

ARCHIVE

PREFACE - Study on the prevalence of facial lipoatrophy in patients infected by HIV virus receiving antiretroviral drugs - FRAN08-005

Head : Cohen-Codar Isabelle

Main objective

Describe the prevalence of the facial lipoatrophy in patients infected by HIV virus and receiving antiretroviral drugs. Describe the prevalence of lipoatrophies and lipodystrophic mixed syndromes.
Evaluate the score of quality of life, using the patients multi-dimensional auto-questionnaire and specific ABCD "Assessment of Body Change and Distress".

Inclusion criteria

Patient infected by HIV virus, receiving antiretroviral drugs for at least 1 month and coming to consultation at his usual follow-up center, during the period of the study, obtaining of the written consent for the collect and exploitation of his personal data.

Flurec - Recurring influenza virus infections and implications in terms of epidemic recurrences and pandemic risk.

Head : Carrat Fabrice, UMR-S 707 / Epidémiologie des maladies infectieuses et modélisation
De Lamballerie Xavier, UMR-D 190, Emergence des pathologies virales

Version 1
Overview

93

Last update : 01/01/2020

ARCHIVE

Flurec - Recurring influenza virus infections and implications in terms of epidemic recurrences and pandemic risk.

Head : Carrat Fabrice, UMR-S 707 / Epidémiologie des maladies infectieuses et modélisation
De Lamballerie Xavier, UMR-D 190, Emergence des pathologies virales

Main objective

To explore cross-protective immunity involving different A/H1N1 viruses (seasonal and pandemic) and the seasonal A/H3N2 virus through data gathered from this study. This study also aims to identify the epidemiological, immunological and virological factors that determine the risk of recurring influenza infections as well as characterise the population's herd immunity and its evolution.

Inclusion criteria

The "influenza" group comprises of patients enrolled after general medical consultation for influenza-like illness during seasonal epidemic. The "non-influenza" group comprises of patients enrolled after general medical consultation during seasonal epidemic for a reason other than influenza, yet that was acute in nature e.g. infectious diarrhoea, minor trauma.

B009 - Follow-up study of patients treated with drotrecogin alfa (activated) (Xigris®) in France

Head : Laboratoire , Eli Lilly France

Version 1
Overview

94

Last update : 01/01/2019

ARCHIVE

B009 - Follow-up study of patients treated with drotrecogin alfa (activated) (Xigris®) in France

Head : Laboratoire , Eli Lilly France

Main objective

Primary objective: evaluate 1-month mortality (at 28 days and 31 days) of patients treated with drotrecogin alpha (activated) in intensive care forsevere sepsis and describe causes of death.
Secondary objectives: characteristics of patients and conditions of use.

Inclusion criteria

All adult patients treated with drotrecogin alpha (activated) in France in the course of routine care in intensive care services.

CEPHEUS - Assessment of lipid-lowering treatment in France

Head : Ferrières Jean, Département d'épidémiologie INSERM UMR1027

Version 3
Overview

95

Last update : 09/05/2017

ARCHIVE

CEPHEUS - Assessment of lipid-lowering treatment in France

Head : Ferrières Jean, Département d'épidémiologie INSERM UMR1027

Main objective

Determine the proportion of patients on lipid-lowering drugs who reach the LDL-C goals recommended in guidelines.

Inclusion criteria

man or woman - adult - treated with lipid-lowering drugs for at least three months, with no dose adjustment for a minimum of six weeks

ABSINTHE - Observational study of the therapeutic strategy in the management of acute sinusitis in primary care

Head : Moore Nicholas, Service de Pharmacologie, CIC-P 0005-INSERM U657- Université Bordeaux Segalen

Version 2
Overview

96

Last update : 09/05/2017

ARCHIVE

ABSINTHE - Observational study of the therapeutic strategy in the management of acute sinusitis in primary care

Head : Moore Nicholas, Service de Pharmacologie, CIC-P 0005-INSERM U657- Université Bordeaux Segalen

Main objective

The study objectives were to describe the management of acute sinusitis in real-life conditions of prescription and to evaluate the effectiveness of the initial therapeutic strategy.

Inclusion criteria

Patient consulting for acute sinusitis diagnosed according to criteria of the practitioner; Patient without a previous episode of acute sinusitis during the two months preceding diagnosis; Patient aged 18 years and over; Patient agreeing to participate in the study; Patient not included in a clinical trial (Huriet-Sérusclat); Patient who may be followed for two months; Patient showing no severe active disease (life-threatening in the next three months).

Please wait...

Partners - FAQ - Contact - Site map - Legal notices - Administration - Updated on December 15 2020 - Version 4.10.05

View Edit Create here